<div id="readability-page-1">The obesity treatment space has been generating plenty of headlines – and sales – over the past few years. GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound) are already delivering noticeably better weight-management results and seeing widespread adoption. At the same time, companies are working on new oral options, giving patients more ways to access and tailor their treatment.<h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. </li><li> Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off </li></ul> This is an industry that is expected to keep on growing over the coming years. The global market for obesity treatments was valued at $15.92 billion in 2024 and is expected to rise to $60.53 billion by 2030, reflecting a 22.31% CAGR from 2025 through 2030, according to Grand View Research. As we head into 2026, Goldman Sachs's global healthcare team has been taking a detailed look at the global anti-obesity medication (AOM) market, noting that it is on the verge of a new stage of growth, one in which the pace and direction will be shaped by a set of emerging factors. These include: &#34;(1) new pricing considerations on the back of LLY and Novo's recently announced GLP-1 pricing deals with the US government, (2) the potential volume/access unlock due to lower prices across multiple different channels in the US (government, commercial, cash pay); (3) increasing OUS penetration from a low base; (4) the launch of daily oral GLP-1 pills from LLY and Novo in the coming months, and (5) increasing consumerization trends which have become a key driver of recent market growth, and could accelerate due to growing public awareness coupled with the emergence of a new delivery ecosystem (DTC/retail/telehealth) that could further transform accessibility and growth dynamics.&#34; The firm's analysts see an opportunity in two of the obesity treatment industry's heavyweights – Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). We've decided to get the lowdown on the pair, and to get a fuller idea of their prospects, have also delved into the TipRanks database. Eli Lilly We'll start with Eli Lilly, a U.S. healthcare giant that achieved a huge milestone last month when it became the first pharmaceutical company ever to reach a $1 trillion market cap, joining a group dominated by tech giants. The main driver behind Eli Lilly's growth has been the commercial success of its GLP-1–based therapies: Mounjaro for type-2 diabetes and Zepbound for obesity. In the first 9 months of 2025, these two drugs together generated almost $25 billion, representing well over half of the company's total revenue. The latter, aimed at obesity, can help patients lose roughly one-fifth of their body weight and shows promise for supporting heart, kidney, and other organ health. Mounjaro, which contains the same active ingredient, tirzepatide, has a significant impact on diabetes, assisting four out of five people with uncontrolled blood sugar reach healthy levels. Such has been its success, tirzepatide has overtaken Merck's Keytruda to become the world's top-selling drug. While competitor Novo Nordisk initially led the market, Mounjaro and Zepbound have grown rapidly in popularity, allowing Lilly to surpass its rival in prescriptions. Lilly gained an advantage partly due to supply issues during Novo Nordisk's 2021 Wegovy launch, giving Lilly room to expand while the company has also scaled manufacturing and distribution more quickly. Looking ahead, Lilly's rapid growth should continue, especially as it prepares to introduce one of the first oral GLP-1 weight-loss treatments. Looking at the company's prospects, Goldman analyst Asad Haider thinks the obesity pill will spur further momentum. &#34;We now assume 2Q26 launch for oral obesity pill orforglipron (vs. prior 3Q26) given the recent receipt of the FDA's National Priority Review Voucher enabling an accelerated approval; the earlier launch adds ~$400mn to our 2026 orforglipron projections which are now $1.5bn (vs. prior $1.1 bn, and Visible Alpha Consensus Data $1.0 bn).,&#34; the analyst said. &#34;We anticipate DTC platforms (such as LLYDirect), the potential expansion of consumer facing retail offerings and an emerging telehealth ecosystem could enable strong cash-pay uptake across a heterogenous and price-elastic target patient population for orforglipron across multiple doses, including the lowest dose given the recent trends toward micro-dosing obesity medications.&#34; &#34;Our 2030 sales estimate for orforglipron (obesity) is now $19bn and $23bn + diabetes (vs. prior $14bn and $18bn + diabetes) reflecting stronger consumer demand driven cash pay dynamics relative to our prior assumptions given strong trends in the consumer channel as evidenced by the recent growth of Zepbound DTC vials,&#34; Haider further added. Accordingly, Haider rates LLY shares a Buy, while he also raised his price target from $951 to $1,145, suggesting the stock will gain 15% over the coming months. (To watch Haider's track record, click here) Most of Haider's colleagues agree with that take. Based on a mix of 18 Buys vs. 2 Holds, the stock carries a Strong Buy consensus rating. Going by the $1,107-and-change average price target, the shares are expected to gain 11.5% in the months ahead. (See LLY stock forecast) </div>

Goldman Sachs' global healthcare team has analyzed the anti-obesity medication market, highlighting Eli Lilly (LLY) and Novo Nordisk (NVO) as key players. The market is expected to grow significantly, driven by new pricing deals, increased accessibility, and the launch of daily oral GLP-1 pills. Eli Lilly's GLP-1 therapies, Mounjaro and Zepbound, have been highly successful, contributing to the company's rapid growth. Goldman analyst Asad Haider predicts strong future sales for Eli Lilly's upcoming oral obesity pill, orforglipron.

LLY and NOVO: Goldman Sachs Weighs In on the Top Obesity Stocks to Watch in 2026